Kyverna Therapeutics, Inc
Fundamentals
Oldest to newest| Line | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating income | −$62.4M | −$142.6M | −$169.8M |
| Net income | −$60.4M | −$127.5M | −$161.3M |
| Operating cash flow | −$52.4M | −$114.3M | −$153.7M |
| Free cash flow | −$53.0M | −$116.5M | −$153.7M |
| Cash | $34.6M | $96.6M | $124.1M |
| Debt | none on file | none on file | $24.7M |
| Shares outstanding | 1.3M | 43.2M | 60.4M |